

## January 27, 2023 | Issue 256

### Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare</u> <u>Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list</u> <u>here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> <u>here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.

> Subscribe here



President Biden <u>signed a memorandum</u> directing HHS to issue guidance ensuring safe <u>access to medication abortion</u>.

FDA concluded that <u>existing regulatory pathways are not appropriate</u> for CBD <u>as a dietary supplement</u>... FDA will <u>continue applying orphan drug</u> <u>marketing exclusivity</u> to indications/uses of a drug, rather than entire diseases, despite <u>a September 2021 appeals court ruling challenging</u> the approach... FDA <u>approved Merck's Keytruda as an adjuvant</u> for non-small cell lung cancer.

CMMI <u>expects to announce</u> 3-4 advanced primary care payment models and a state-based Medicare total cost of care model this year. CDC Director Rochelle Walensky <u>announced agency organizational</u> <u>changes</u>, including a new Office of Health Equity and Office of Public Health Data, Surveillance and Technology, and a Director for External Affairs.





# Healthcare law and policy news

CMS announced <u>a record 16.3M individuals signed up for ACA marketplace</u> <u>coverage</u> during open enrollment, including 3.6M first-time enrollees.

Elevance Health <u>plans to acquire BCBS Louisiana</u>... AmerisourceBergen <u>will</u> <u>change its name to Cencora</u> to reflect its "global reach, impact, and purpose"... Walgreens is <u>exploring sale of its pharmacy automation</u> business... Minnesota Attorney General <u>asked Sanford and Fairview to delay</u> their merger.

Amazon <u>launched RxPass</u>, a \$5/month subscription for Prime members to receive all eligible generic medications... OptumRx <u>launched Price Edge tool</u> to help consumers compare direct-to-consumer and insurance prices for generic drugs... Dollar General <u>will pilot mobile health clinics</u> at three Tennessee stores... UnitedHealthcare launched a <u>virtual behavioral health</u> program... Kroger Health <u>launched clinical trial sites</u> at <u>selected pharmacies/retail clinics</u>.

JAMA studies found: (1) loosened restrictions on buprenorphine prescribing during the pandemic <u>was not associated with a rising share of</u> <u>buprenorphine-involved</u> overdoses; (2) telehealth <u>has not increased access to, or</u> <u>improved quality</u> of, opioid use disorder care; and, (3) clinical quality/patient experience measures <u>were marginally better for health system providers than</u> <u>non-system providers</u> in 2018, but spending/prices were substantially higher.

A <u>Qualtrics survey</u> found <u>52% of healthcare employees believe they are paid</u> <u>fairly</u>, the lowest of any industry.

NYU and RWJF <u>released</u> a <u>Congressional District Health Dashboard</u>... CDC researchers reported: (1) <u>31.8% of adults</u> and <u>27.2% of children</u> have a seasonal allergy, eczema, or food allergy, and, (2) <u>substance use disorders</u> <u>cost employer-sponsored</u> health plans <u>\$35.3B/year</u>.



# Special Section: COVID-19 and Other Respiratory Illnesses News

An FDA <u>advisory committee recommended</u> (21 to 0) to harmonize the primary series of COVID-19 vaccines with the new bivalent booster formulation and

to <u>move to a single annual vaccine dose for most Americans</u>, updated to reflect circulating strains of the virus.

A <u>CDC study found</u> a bivalent mRNA booster COVID-19 vaccine dose for previously vaccinated persons was roughly 50% effective at preventing symptomatic infection from Omicron XBB/XBB.1.5 for at least three months... An <u>NEJM study found</u> the bivalent vaccine was significantly more effective at protecting against severe illness, hospitalization, and death than the monovalent vaccine.

FDA <u>withdrew authorization</u> of the COVID-19 antibody therapy Evusheld, given as a pre-exposure treatment for high-risk individuals, after determining <u>it was ineffective against current strains of the virus</u>.

A study <u>estimated 268,176 excess deaths were incorrectly not reported as COVID-19 deaths</u> during the first two years of the pandemic (March 2020 to February 2022), representing 23.7% of all excess deaths during that time... A <u>KFF analysis found</u> of individuals who have ever had COVID, the share who say they currently or have ever had long COVID declined from 35% in June 2022 to 28% in January 2023.

An <u>advisory board draft report recommends</u> "federal department-level review" of all research aiming to enhance the transmissibility and/or virulence of any pathogen.

FCC issued <u>a declaratory ruling</u> stating federal and state governments and their partners <u>can make Medicaid enrollment calls without running afoul</u> of bans on robocalls and robotexts, expanding approaches governments can use to better facilitate continuous coverage for Medicaid enrollees after pandemic-related policies expire.

Questions or comments, please send to <u>us-hclspractice@kpmg.com</u>.



#### Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please <u>click here</u>. If you wish to unsubscribe from all KPMG communications, please <u>click here</u>.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2023 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP295619-1E

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.